Početna › Epitelni karcinom jajnika › Ohio
Kliničke studije za Epitelni karcinom jajnika u državi Ohio
10 studija za Epitelni karcinom jajnika traži sudionike na lokacijama u državi Ohio.
Gradovi u državi Ohio
Službeni tekst studije (engleski)
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
- Research Site, Cleveland
U tijeku regrutacijaFaza 3
Od 18 godina i više · Žene · Ažurirano 1. lis 2026. · NCT07851025A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Metrohealth Medical Center - Cleveland /ID# 276664, Cleveland
- Cleveland Clinic - Cleveland /ID# 276133, Cleveland
- Cleveland Clinic - Cleveland /ID# 278273, Cleveland
- i još 3
U tijeku regrutacijaFaza 2
Od 18 godina i više · Žene · Ažurirano 29. ruj 2026. · NCT06890338Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Cleveland
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT05867251ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cleveland Clinic, Cleveland
- Toledo Clinic Cancer Center, Toledo
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT05059444Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer
- Department of Subspecialty Care for Women's Health Women's Health; Division of Gynecologic Oncology, Case Comprehensive Cancer Center, Cleveland
U tijeku regrutacija
Od 18 godina i više · Žene · Ažurirano 6. kol 2026. · NCT06386887AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, Blue Ash
- Research Site, Dayton
- Research Site, Sylvania
U tijeku regrutacijaFaza 3
Od 18 godina i više · Žene · Ažurirano 21. srp 2026. · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Miami Valley Hospital South, Centerville
U tijeku regrutacijaFaza 3
Od 18 godina i više · Žene · Ažurirano 2. srp 2026. · NCT06819007A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Stefanie Spielman Comprehensive Breast Center, Columbus
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 27. ožu 2026. · NCT06395519CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- The James Cancer Hospital and Solove Research Institute - Ohio State University, Columbus
U tijeku regrutacijaFaza 2
Od 18 godina i više · Žene · Ažurirano 23. pro 2025. · NCT06690775Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Cleveland Clinic, Cleveland
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 15. kol 2025. · NCT04429542Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.